Ranking Invest

Recursion Pharmaceuticals, Inc.

Segmento: Healthcare Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Indicadores Básicos

Valor de Mercado

$ 2.20 Bi

IVR

-0.14

IVR2

-0.59

Índices de Previsibilidade

Faturamento

0.31

Lucro

0.24

Margem

0.59

Índices de Tendência

Faturamento

7.77

Lucro

-9.87

Margem

0.36

Índices de Endividamento

DIV/PAT

-0.44

DIV/L4T

0.71

Dívida Líquida

-$ 407.54 Mi

Patrimônio Líquido

$ 933.95 Mi

L4T

-$ 574.61 Mi

MM4T

-1595.66%

Dívidas
Dividendos
Cotação: $5.09

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre